NCT01500733View on ClinicalTrials.gov

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

January 5, 2012

Primary Completion Date

June 20, 2014

Study Completion Date

September 30, 2034

Conditions
LeukemiaLeukemia, LymphocytycCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)
Interventions
DRUG

PCI 32765

420 mg daily

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH